EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals to report third quarter 2015 financial results and hold an investment community conference call on Friday, November 13, 2015.
No Link Between Oral Fluoroquinolones, Uveitis in Large Study
According to a new retrospective study, there are no data to support an association between the use of oral fluoroquinolones and an increased risk for uveitis. Medscape Medical News
JEDI T-cells provide unique technology to study, visualize immune responses and immunotherapies
When it comes to fending off disease and helping prevent people from falling ill, the body’s immune system — armed with T-cells that help eliminate cancer cells, virus-infected cells and more — is second to none. But exactly how the immune system wor…
Get Ready for MIPS — or Opt Out
(MedPage Today) — Medicare’s newest quality reporting program will look at data from 2017
Uncategorized
Avedro receives approval in China for KXL cross-linking system
Avedro has received approval from the China Food and Drug Administration for its KXL cross-linking system for the treatment of keratoconus and post-LASIK ectasia, according to a company press release. The approval of the KXL system is the result of a m…
Bruker Reports Third Quarter 2015 Financial Results
BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation (NASDAQ: BRKR) today reported financial results for its third quarter ended September 30, 2015. Bruker’s revenues for the third quarter of 2015 were $396.1 million, a decline of 5.6 percent compared to the third quarter of 2014. Excluding a 2.8 percent negative effect from divestitures, and a 10.9 percent negative effect from changes in foreign exchange rates, Bruker reported year-over-year organic revenue growth of 8.1 percent in the third